PureTech Health (NASDAQ:PRTC) Trading Up 3.6% - Here's What Happened

Key Points

• PureTech Health's stock price rose by 3.6% during trading on Thursday, reaching a high of $19.01 from a previous close of $18.35.
• Weiss Ratings issued a "sell (d)" rating for PureTech Health, contributing to a consensus rating of "Sell" among analysts.
• Various institutional investors have recently increased their holdings, with Pentwater Capital Management multiplying its stake by 39.2% in the first quarter.

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report)'s stock price was up 3.6% during trading on Thursday . The stock traded as high as $18.51 and last traded at $19.01. Approximately 1,150 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 4,836 shares. The stock had previously closed at $18.35.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a "sell (d)" rating on shares of PureTech Health in a research report on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PureTech Health presently has a consensus rating of "Sell".

PureTech Health Trading Up 3.6%

The stock's 50-day moving average is $17.56 and its 200-day moving average is $17.68.

Institutional Investors Weigh In On PureTech Health

A number of institutional investors have recently modified their holdings of the company. Pentwater Capital Management LP boosted its stake in shares of PureTech Health by 39.2% in the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock valued at $664,000 after purchasing an additional 9,449 shares during the last quarter. Diadema Partners LP bought a new stake in shares of PureTech Health in the 2nd quarter valued at $126,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of PureTech Health in the 2nd quarter valued at $29,000. 0.04% of the stock is owned by institutional investors.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.